B of A Securities Downgrades Chemours to Neutral, Lowers Price Target to $37
Portfolio Pulse from richadhand@benzinga.com
B of A Securities analyst Matthew DeYoe downgraded Chemours (NYSE:CC) from Buy to Neutral and lowered the price target from $41 to $37.
June 22, 2023 | 1:33 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Chemours (NYSE:CC) has been downgraded from Buy to Neutral by B of A Securities, with a reduced price target of $37, down from $41.
The downgrade from Buy to Neutral and the reduction in price target from $41 to $37 by B of A Securities analyst Matthew DeYoe may negatively impact Chemours' stock price in the short term, as investors may perceive this as a sign of reduced growth potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100